AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04422275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo (lactose monohydrate) drug will be dissolved in 240 ml of nasal saline lavage.
Study NCT05535361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome
Description: The surgeon verifies the intestinal diameter and selects the appropriate device diameter size. The device is introduced into the lumen of the intestine and advanced about 5-10cm. The surgeon uses 4-0 sutures placed in the seromuscular layer to secure the XL1 Coil within the intestine. The surgeon places metal clips on proximal and distal sutures and in the mesentery adjacent to the XL1 Coil ends to mark the location for radiologic evaluation. The surgeon releases the XL1 Coil and closes the enterotomy.
Study NCT06351293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defyne Treatment in Nasolabial Fold
Description: Defyne will be injected into left or right nasolabial fold, per randomization.
Study NCT06351293 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RHA3 Treatment in Nasolabial Fold
Description: RHA3 will be injected into left or right nasolabial fold, per randomization.
Study NCT05769101 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ingestion of a Post-Workout Supplement
Description: The Post-Workout Supplement is administered 15 minutes after the completion of training sessions. No supplementation is administered in non-training days. The Resistance Training is performed in alternate days. The training Protocol is: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Alternate Box Step-Ups, Bench Press; Parallel Squat; Up-right Row; Deadlift; Alternate Lunges; Shoulder Press; Leg Extension). The participants perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2.5 to 5 kg are added for the next set. Also, whole-body Perceptual Response is assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing.
Study NCT05769101 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ingestion of a Maltodextrin Supplement
Description: The Maltodextrin Supplement is administered 15 minutes after the completion of training sessions. No supplementation is administered in non-training days. The Resistance Training is performed in alternate days. The training Protocol is: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Alternate Box Step-Ups, Bench Press; Parallel Squat; Up-right Row; Deadlift; Alternate Lunges; Shoulder Press; Leg Extension). The participants perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2.5 to 5 kg are added for the next set. Also, whole-body Perceptual Response is assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing.
Study NCT06551012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice
Description: Participants will consume 2 x 70 ml bottles of nitrate-rich beetroot juice for a 7 day period prior to exercise testing
Study NCT06551012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot juice with nitrate extracted
Description: Participants will consume 2 x 70 ml bottles of beetroot juice with nitrate extracted for a 7 day period prior to exercise testing
Study NCT04896294 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Hygienic procedure (toothbrushing using HAP-containing toothpaste)
Description: Toothbrushing using standardised technique and pear-sized amount of HAP-containing toothpaste twice daily for 1 month.
Study NCT04896294 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hygienic procedure (toothbrushing using Zn Mg HAP-containing)
Description: Toothbrushing using standardised technique and pear-sized amount of Zn Mg HAP-containing toothpaste twice daily for 1 month.
Study NCT04896294 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hygienic procedure (toothbrushing using FAP-containing toothpaste)
Description: Toothbrushing using standardised technique and pear-sized amount of FAP-containing toothpaste twice daily for 1 month.
Study NCT05594420 — intervention group
Intervention type: PROCEDURE
Intervention: Mitral valve replacement
Description: Mitral valve replacement through median sternotomy and minimally invasive approach
Study NCT06068530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHA/piperaquine and a SLD-PQ
Description: Participants in Arms 1 and 2 will receive three rounds of antimalarial drugs - each round starting on the day of vaccination (Day 0) at Study Months 0, 1, and 2. Each round consists of three daily doses of co-formulated dihydroartemisinin/piperaquine on Day 0, 1, and 2 (i.e. the day of vaccination and each day for 2 days after). The drug dose is based on the weight of the participant at the first visit (M0D0). Dihydroartemisinin/piperaquine tablets (Shanghai Fosun Pharmaceutical Co., Ltd.) for adult participants each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a therapeutic dose range between 2-10 mg/kg/day dihydroartemisinin and 16-26 mg/kg/dose piperaquine. In addition, each participant will receive a single low dose primaquine on the day of vaccination (Day 0; Table 4). One single low dose primaquine of approximately 0.25 mg/kg (Thai Government Pharmaceutical Organisation) will be administered. Children under 10kg do not receive PQ.
Study NCT06068530 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Study vaccine R21/Matrix-M™
Description: The mixing prior to administration strategy will involve withdrawal of 0.5 mL antigen from one vial of R21 Malaria vaccine and adding it to Matrix-M1 vial. 0.5 mL of R21 antigen shall be withdrawn from another vial of R21 Malaria vaccine and be added to the same Matrix-M1 vial. The total volume in Matrix-M1 vial will be 1.5 mL. After addition the content will be mixed gently, and 0.75 mL of the mixture will be withdrawn and administered to participants. Each dose of 0.75mL (after mixing of R21 with Matrix-M1) will contain 10 µg of R21 and 50 µg for participants 14 years and older. In children up to 14 years a 5 μg will be used.
Study NCT05225831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells
Description: A single infusion of CD19 and CD22 CAR-T cells.
Study NCT05013840 — intervention group
Intervention type: BEHAVIORAL
Intervention: Filling in an online survey
Description: Physicians are asked to fill in an online survey regarding 1) goals to treat patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.
Study NCT05225831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide,Fludarabine
Description: Given
Study NCT06449885 — intervention group
Intervention type: OTHER
Intervention: patients receive optimal treatment or follow-up according to the characteristics of the disease
Description: Patients with MZL who are eligible for enrollment will be evaluated by the investigator and the enrolled patients will receive long-term follow-up after collecting medical history information, biological samples, and oncology data according to the study protocol. This study does not specify a detailed treatment modality, and patients receive optimal treatment or follow-up according to the characteristics of the disease.
Study NCT06089421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Information Assistant
Description: Participants assigned will receive a link to Genetic Information Assistant for pre-test counseling.
Study NCT06089421 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telegenetics with UVA genetic counselor
Description: Participants assigned will have a pre-test counseling session via a telegentics visit with a genetic counselor.
Study NCT05406037 — intervention group
Intervention type: BIOLOGICAL
Intervention: Venous sample
Description: at Day 0, Day 3, Day 7, Day 14, Day 28 (7 ml blood sample collecting on dry tube) D0 = Diagnostic day
Study NCT05744050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low energy density lunch
Description: Particpants will be provided with a lunch low in energy density (\~1.1kcal/g)
Study NCT05744050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medium energy density lunch
Description: Participants will be provided with a lunch medium in energy density(\~1.7kcal/g)
Study NCT05521165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic exercises
Description: strengthening exercises for gluteus medius and APTA guided program for NSCLBP
Study NCT05744050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High energy density lunch
Description: Participants will be provided with a lunch high in energy density (\~3kcal/g)
Study NCT06129409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-0796
Description: Orally administered capsules
Study NCT06129409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NT-0796
Description: Orally administered capsules
Study NCT04727008 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CXCR4 modified anti-BCMA CAR T cells
Description: intravenous infusion
Study NCT05634122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: Group treatment protocol of 8 weeks of 90 minutes sessions Session 1: Presentation of the general ACT therapy concept. Session 2: Value analysis I. Session 3: Value analysis II. Session 4: Value analysis third Session 5: Values and feelings. Session 6: Drink one direction. Session 7: Dare and change. Session 8: Ready to act with ACT. Treatment as usual (TAU) Standard pharmacological treatment for patients with chronic pain.
Study NCT05634122 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Standard pharmacological treatment for patients with chronic pain
Study NCT04422275 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-Concentration Essential Oil
Description: Low-concentration essential oil will include 0.1 ml of essential oil per jar.
Study NCT04422275 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Low-Concentration Essential Oil
Description: Low-concentration essential oil will include 0.1 ml of essential oil per jar.
Study NCT04601376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Monitoring Tool
Description: a text-messaged based outcomes collection system
Study NCT04644731 — intervention group
Intervention type: DEVICE
Intervention: Aquadex™ System
Description: Ultrafiltration for fluid removal
Study NCT04325347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality application
Description: Virtual Reality application with a VR goggle
Study NCT04323475 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacteriophage cocktail spray
Description: Study intervention consists of a dosage-metered airless spray containing a cocktail of 14 bacteriophages at a concentration of 1.4 x 10\^8 PFU/mL for an effective dosage of 2.5 x10\^5 PFU/cm\^2 of burned area. The study intervention will be applied in conjunction with standard of care.
Study NCT04323475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeroform
Description: Standard of care will consist of Xeroform primary dressing and Kenacomb topical antibiotic cream (for wounds with signs of localized infection)
Study NCT04323475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xeroform
Description: Standard of care will consist of Xeroform primary dressing and Kenacomb topical antibiotic cream (for wounds with signs of localized infection)
Study NCT05159180 — intervention group
Intervention type: DEVICE
Intervention: cardioz mapping
Description: Patients will be submitted to mapping of both voltage and tissue impedance.
Study NCT05250856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP-201
Description: CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~5 μg of PPE per mg of PLGA.
Study NCT05250856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CNP-201
Description: CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~5 μg of PPE per mg of PLGA.
Study NCT05250856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, (0.9% Sodium Chloride for IV infusion)
Study NCT05180812 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ExoNet Tuned to Gravity Support
Description: This study's primary goal is to test the safety, feasibility, and efficacy of the ExoNET device developed in the Robotics Lab at the Shirley Ryan AbilityLab. We want to observe if individuals using the ExoNET tuned to gravity support will notice a reduction in bicep muscle activity, leading to an improvement in functional outcome measures in stroke patients.
Study NCT05180812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExoNet Tuned to Gravity Support
Description: This study's primary goal is to test the safety, feasibility, and efficacy of the ExoNET device developed in the Robotics Lab at the Shirley Ryan AbilityLab. We want to observe if individuals using the ExoNET tuned to gravity support will notice a reduction in bicep muscle activity, leading to an improvement in functional outcome measures in stroke patients.
Study NCT06468358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB1410
Description: anti-PD-1/TIM3 bispecific antibody
Study NCT06468358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB4330
Description: anti-claudin18.2/IL-10 fusion protein
Study NCT05192603 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low FODMAP or SSRD
Description: The participants are given oral and written information about each diet. No food is delivered from the investigator to the participant
Study NCT04909151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (walking speed: 0.5km/h)
Description: Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
Study NCT04909151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (walking speed: 0.8km/h)
Description: Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
Study NCT04909151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (walking speed: 1.1km/h)
Description: Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
Study NCT06239818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMt)
Description: Participants will be asked to use the photobiomodulation (PBM) device for 20 minutes, daily (e.g., Monday - Sunday) for a total of 30 days. The device will be preprogrammed and automatically switched off after 20 minutes.
Study NCT06239818 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The patient is provided with verbal and written education including what a mild traumatic brain injury (mTBI) is, favorable expectations for recovery, and advice about how to manage specific symptoms. Relative rest for the first 24-48 hours after an mTBI is recommended as the main goal is to alleviate symptoms and reduce demands on the brain. After an initial period of relative rest and symptom stabilization, patients are encouraged to gradually resume normal daily activities as tolerated. Physical and cognitive activities can be progressively resumed at a pace that does not worse existing or create new symptoms. Education, return to activity advice, and symptom management are all reviewed in subsequent visits as needed.
Study NCT06239818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The patient is provided with verbal and written education including what a mild traumatic brain injury (mTBI) is, favorable expectations for recovery, and advice about how to manage specific symptoms. Relative rest for the first 24-48 hours after an mTBI is recommended as the main goal is to alleviate symptoms and reduce demands on the brain. After an initial period of relative rest and symptom stabilization, patients are encouraged to gradually resume normal daily activities as tolerated. Physical and cognitive activities can be progressively resumed at a pace that does not worse existing or create new symptoms. Education, return to activity advice, and symptom management are all reviewed in subsequent visits as needed.
Study NCT06211855 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: doppler assesment
Description: In all cases, the measurement, including UA PI and MCA PI, was measured with a 6-4 MHz convex transabdominal probe. All measurements were made by an obstetrician (Ş.D.) with 28 years of experience. Doppler measurements were collected from the proximal third of the MCA and the free-floating segment of the umbilical cord, ensuring that the angle of insonation was as close to zero as feasible and that fetal movements were absent
Study NCT05228340 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flexor tenotomy
Description: Minimally-invasive percutaneous needle flexor tenotomy of the long digital flexor tendon
Study NCT06403371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride varnsh
Description: Fluoride varnish was applied to the teeth surfaces before aligner therapy
Study NCT06403371 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline was applied to the teeth surfaces before aligner therapy
Study NCT04792892 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Patients will be answering questionnaires at 0, 3, 12, 36, 60 and 120 months
Study NCT06461754 — intervention group
Intervention type: OTHER
Intervention: Sonographic evaluation of diaphragm and lung
Description: While the patient in a semi-sitting position (20-40 degree), by ultrasound, the diaphragm thickness was measured in the zone of apposition, on the mid-axillary line among the 8th and 10th intercostal spaces, using a 7-10 MHz linear probe in (M) mode. at the end of expiration and at the end of inspiration by capturing nearly three images during spontaneous patient breathing. The average of three DTI measurements was calculated In lung ultrasound, 2-4 MHz convex ultrasound probe in (B) mode was employed. We implemented a modified LUSm in our investigation, which assessed four lung regions on each side.
Study NCT04538105 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Saline Articular Nerve Branch Block
Study NCT04538105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Articular Branch Block (ABB)
Description: 0.5% Bupivacaine with epinephrine 1:200,000 (Articular Branch Block)
Study NCT06197490 — intervention group
Intervention type: BIOLOGICAL
Intervention: Evaluation of the parameters of the lithiasis assessment before and after KAFTRIO initiation
Description: Collection of Uricuria, phosphaturie, calciuria, magnesuria, glycosuria, citraturia, oxaluria, before and after initiation of KAFTRIO
Study NCT06197490 — intervention group
Intervention type: DRUG
Intervention: Collection of Arterial pressure, metabolic data, kidney function, proteinuria and hematuria before and after KATRIO initiation
Description: Arterial pressure, glycemia, glycated hemoglobin, lipid profile, weight, serum and urinary electrolytes, hepatic check, complete blood count, calcium phosphate balance and urinary sediment analysis before and after initiation of KAFTRIO
Study NCT05367999 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: initial Paroxysmal Event Profile
Description: The initial Paroxysmal Event Profile (iPEP) was derived from the paroxysmal event profile (PEP) and paroxysmal event observer (PEO) to provide a diagnostic tool aiming to differentiate between the most common underlying reasons for TLOC presentations: syncope, epilepsy, and dissociative seizures. The iPEP is a 35-item questionnaire developed from the PEP and PEO.5,25 The 5-point frequency scales used in response to each symptom in the PEP and PEO have been replaced with a binary 'present'/'not present' classification in recognition of the fact that the target patient group may have experienced only one or a few episodes of TLOC.
Study NCT05731960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10 mg IV dexamethasone provided immediately after spinal anesthesia
Study NCT05731960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: 10 mg IV metoclopramide provided immediately after spinal anesthesia
Study NCT05073094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Esmolol injected intravenously and added to cardioplegia solution
Study NCT05073094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent volume of placebo (saline) as a bolus before aortic cross-clamping and in the cardioplegic solution
Study NCT04822584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib Oral Product
Description: Baricitinib 4 mg/day orally for 36 weeks
Study NCT04822584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once a day orally for 36 weeks